Dr. Bermas is the director of the Lupus Center and co-director of the Program in Pregnancy and Rheumatic Diseases at Brigham and Women’s Hospital in Boston.
References
- Trussel J. The cost of unintended pregnancy in the United States. Contraception. 2007; 75:168-170.
- Hoppe DE, Bekkar BE, Nager CW. Single-dose systemic methotrexate for the treatment of persistent ectopic pregnancy after conservative surgery. Obstet Gynecol. 1994;83:51-54.
- Bawle E, Conard J, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology. 1998;57:51-55.
- Chervenak F, McCullough LB. Responsibly counselling women about the clinical management of pregnancies complicated by severe fetal anomalies. J Med Ethics. 2012;38:397-398.
- Wilkinson D. Fatal fetal paternalism. J Med Ethics. 2012;38:396-387.
- Heuser CC, Eller AG, Byrne JL. Survey of physicians’ approach to severe fetal anomalies. J Med Ethics. 2012;38:391-395.
- Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: Low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993;47:533-539.
- Kozlowski RD, Steinbrunner JV, Mackenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990;88:589-592.
- Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM. 1999; 92:551-563.
- Schmitz D. Terminating pregnancy after prenatal diagnosis—with a little help of professional ethics? J Med Ethics. 2012;38:399-402.
